Radnor Capital Management LLC Grows Holdings in Becton, Dickinson and Company (NYSE:BDX)

Radnor Capital Management LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,937 shares of the medical instruments supplier’s stock after buying an additional 48 shares during the quarter. Radnor Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $708,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. WR Wealth Planners LLC lifted its stake in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares during the last quarter. Clear Creek Financial Management LLC lifted its position in Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares during the last quarter. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Central Pacific Bank Trust Division grew its position in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 45 shares during the last quarter. Finally, Capital Advisors Ltd. LLC raised its stake in shares of Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 48 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $240.10 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $259.33. The firm has a market cap of $69.40 billion, a P/E ratio of 49.40, a P/E/G ratio of 1.76 and a beta of 0.43. The business’s 50 day moving average price is $237.53 and its 200-day moving average price is $235.16.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BDX. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James lowered their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.